THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH LAW.

It is anticipated that the Swedish Companies Registration Office will register the merger on 23 October 2026. Upon registration of the merger, Biosergen will be dissolved, and all of its assets and liabilities will transfer to Flerie. Following completion of the merger, Biosergen's business operations will be contributed to a newly formed subsidiary of Flerie Invest AB, which is a wholly owned subsidiary of Flerie.

As a result of the approval granted by the Swedish Companies Registration Office and the forthcoming registration of the merger, Biosergen will be delisted from Nasdaq First North Growth Market. The last day of trading in Biosergen's shares on Nasdaq First North Growth Market is expected to be 22 October 2026.

The shareholders listed in Biosergen's share ledger as of the record date 26 October 2026 will receive merger consideration. For every thirty-one (31) shares held in Biosergen, shareholders will receive one (1) newly issued ordinary share in Flerie. No actions will be required from Biosergen's shareholders in order to receive the merger consideration.

Biosergen's shareholders are expected to receive these new shares, i.e. the merger consideration, on or about 28 October 2026. Trading in Flerie shares will proceed as normal and will not be affected by the merger process.

For more information, please contact:

Tine Kold Olesen, CEO

E-mail: tine.olesen@biosergen.net

Telephone: +45 3135 5707

Mark Beveridge, CFO

E-mail: mark.beveridge@biosergen.net

Telephone: +46 76 805 8288

The information was submitted for publication, through the agency of the contact person above, on 16 October 2026

Biosergen's Certified Advisor is DNB Carnegie Investment Bank AB (publ).

About Biosergen

Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen's mission is to develop the drug candidate BSG005, including new formulations, into a new first-line treatment choice for resistant and/or difficult-to-treat invasive fungal infections. The company strives to set a new standard for combating these infections where current treatments fall short, thereby saving thousands of lives every year among immunocompromised cancer patients, transplant recipients and AIDS patients.

Important Information

In the information below, "this press release" refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the proposed legal merger between Flerie and Biosergen shall be made solely on the basis of information stated in the actual notices to attend Flerie's and Biosergen's extraordinary general meetings, and the merger document relating to the merger, and to independent analyses of the information therein. You should read the merger document, which will be available before the extraordinary general meetings which will decide on the issues set forth herein, to obtain more complete information on the merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.

This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective Companies or the merged company's control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company's management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Flerie nor Biosergen undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Flerie's and Biosergen's past performance does not guarantee, and does not represent, the future performance of the merged company. Furthermore, Flerie, Biosergen and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release. Furthermore, it is not certain that the merger will be carried out in the manner and within the time frame described in this press release or at all.